Company Profile
MDxHealth Stock Price, News & Analysis
- Ticker:
- MDXH
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- Belgium and listed in the U
Stock performance
0.44 USD (+1.04%)
Close
Last updated: August 6, 2026
32.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MDXH closed up 1.04% at $0.4381. No new same-company headline was identified in the current news window.
Company overview
Precision Urologic Diagnostics
MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.
Prostate Cancer Menu
The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic, epigenomic, and exosomal technologies.
ExoDx Integration
The acquired ExoDx urine-based prostate test broadens the diagnostic menu and is being integrated into MDxHealth’s laboratory, sales, and reimbursement infrastructure.
Portfolio Refocus
MDxHealth is exiting the Resolve UTI business to concentrate investment on prostate cancer and related urologic oncology opportunities.
Future catalysts
MDxHealth’s catalysts are oncology-diagnostic adoption, reimbursement, and whether the company can keep building recurring test revenue. The next step that matters is continued workflow expansion.
Recent news
- 01
- 02
- 03
- 04
- 05
Mdxhealth Reports Q1-2026 Results
Source: MDxHealth
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MDxHealth (MDXH)?
MDxHealth (MDXH) most recently closed at 0.44 USD, a +1.04% move versus the previous session.
What is the market cap of MDxHealth (MDXH)?
MDxHealth currently has a market capitalization of 32.9M USD on BioPharmSignal.
What does MDxHealth do?
Precision Urologic Diagnostics MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases. Prostate Cancer Menu The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic, epigenomic, and...
On which exchange is MDXH stock listed?
MDxHealth (MDXH) is associated with NASDAQ, Belgium and listed in the U, MedTech.
What is Precision?
Precision Urologic Diagnostics MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.
Which conditions is MDxHealth targeting with Precision?
MDxHealth is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does MDxHealth describe recent progress with Precision?
MDxHealth’s catalysts are oncology-diagnostic adoption, reimbursement, and whether the company can keep building recurring test revenue. The next step that matters is continued workflow expansion.
What is Urologic?
Precision Urologic Diagnostics MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.